A tool to help patients decide on contralateral prophylactic mastectomy for breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness of an online decision support tool designed to assist patients with newly diagnosed breast cancer in making informed choices about contralateral prophylactic mastectomy (CPM). The tool provides evidence-based information regarding the risk of contralateral breast cancer and the potential life expectancy benefits of undergoing CPM. Patients will use this tool during consultations with their breast cancer surgeon and will complete questionnaires before and after the consultation to assess its impact on their decision-making process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed ductal breast carcinoma in situ (DCIS) or stage I-III sporadic unilateral invasive breast cancer
* Able to speak read or write English

Exclusion Criteria:

* Patients with previous breast cancer
* Prior history of bilateral prophylactic mastectomy
* Known to have a germline mutation that predisposes them to an increased risk of breast cancer (e.g. BRCA1/2) and/or they are considered at high risk for contralateral breast cancer on the basis of a strong family history of cancer

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Abenaa M Brewster — M.D. Anderson Cancer Center
• Study coordinator: Abenaa M Brewster
• Email: abrewster@mdanderson.org
• Phone: 713-745-4949

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized tumor vaccine with checkpoint inhibitors for triple negative breast cancer

  This phase I trial will test whether a personalized tumor membrane vesicle (TMV) vaccine, given alone or with pembrolizumab or ipilimumab, can boost immune response and help control disease in adults with triple negative breast cancer.

  Recruiting at 4 sites Phase 1 Emory University · Atlanta, Georgia and 3 other locations · NCT06324240

• Using minoxidil to treat hair loss in breast cancer patients on endocrine therapy

  This study is testing if a hair loss treatment called minoxidil, given either as a foam or a pill, can help women with breast cancer who are losing their hair due to cancer therapy.

  Recruiting Early Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05417308

• Combining Tumor Treating Fields with Cabozantinib or Pembrolizumab and Nab-Paclitaxel for Advanced Solid Tumors

  This study is testing a new treatment that combines tumor treating fields with two different cancer drugs to see if it helps people with advanced solid tumors in the abdomen or chest.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT05092373

• Combining Olaparib with Cediranib or AZD6738 for Advanced Breast Cancer with BRCA Mutations

  This study is testing if combining the drugs olaparib with either cediranib or AZD6738 can help women with advanced breast cancer that has BRCA mutations feel better after they’ve already tried other treatments.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04090567

• Imlunestrant and Abemaciclib for ER+ Breast Cancer with Minimal Residual Disease

  This Phase 2 trial tests whether taking imlunestrant and abemaciclib together can help people with ER-positive breast cancer who still have detectable cancer after initial treatment.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07191717

• Using metformin to treat insulin resistance in women with early-stage breast cancer after chemotherapy

  This study is testing if metformin can help women with early-stage breast cancer who have finished chemotherapy and are struggling with insulin resistance to improve their health.

  Recruiting Phase 3 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06763328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.